The $4 million investment by the Bill & Melinda Gates Foundation in Affinivax Inc.'s vaccine technology "provides us the opportunity and the runway to build out this platform and get additional points of validation, which will allow us to bring on potentially new funders, but also pharma partners," said CEO Steven Brugger.